Siemens to showcase nuclear medicine innovations at BNMS 2009

12 March 2009

Siemens has announced it will be presenting its latest product advancements at the British Nuclear Medicine Society’s Annual Meeting from the 27-29 April 2009 at the Manchester Central Convention Complex.

This includes information on its innovation, the Biograph mCT for molecular Computed Tomography as well as the Symbia T16 TruePoint SPECT CT and the world’s first intelligent SPECT technology, IQ SPECT. Siemens will also be offering information from PETNET Solutions, its PET tracer division that supplies biomarkers for imaging.

The newly launched Biograph mCT integrates the first advanced HD PET platform and the world’s first Adaptive Spiral CT to create a next generation dual modality device for a new level of integrated imaging. It can offer whole body scans in five minutes at an ultra low dose for the optimum workflow efficiency.

At the stand, PETNET Solutions will also be providing information on its range of PET radiopharmaceuticals for imaging. Equipped to meet the evolving needs of molecular imaging, PETNET Solutions delivers innovative products and services to optimise the value of diagnostic scanning services.

Other products on show will include the: Symbia T16 TruePoint SPECT CT that combines a variable angle dual detector SPECT with a 16-slice CT for rapid, accurate attenuation correction, precise localisation and advanced options for cardiology including calcium scoring in 15-20 seconds; information on the world’s first intelligent SPECT technology, IQ SPECT, for improved image quality in clinically challenging situations. When combined with the Symbia S and Symbia T series systems, IQ SPECT is able to provide more information on the heart in five minutes, in comparison to 20 minutes using traditional SPECT.

“Siemens is leading the way in nuclear medicine innovation and new product offerings such as the Biograph mCT highlight our commitment to deliver evolving solutions that benefit both staff and patient,” said Lawrence Foulsham, Product Manager for Molecular Imaging and Oncology at Siemens Healthcare. “True dual modality imaging is ideal for today’s healthcare budgets and offers not only the latest technology but also provides a more comfortable experience for the patient.”

Bookmark this page

To top